The best stocks to play in a down market tend to be found in sectors such as consumer staples, utilities, healthcare and REITs. Healthcare in particular offers a plethora of innovative companies with multi-bagger potential based on breakthrough technologies that have either been overlooked or oversold hastily due to market conditions.
Memorial day has passed and savvy investors are settling back into their workstations, discounted prices on healthcare stocks will not last long, so today our report features several oversold or undervalued healthcare equities with near term bullish potential.
Wearable Health Solutions, Inc. (OTCMKTS: WHSI) is the first oversold healthcare opportunity to research today. The company is positioned to capture a controlling share of an almost trillion-dollar opportunity in the PERS market within the next eight years, and it’s currently trading for just $0.01 per share. This true penny stock has positioned itself for a monster 2022 and the current market conditions have created an opportunity for uninitiated investors to catch up on the story and enter at a favorable price.
WHSI has had success with its iHelp device, a next-generation personal emergency response solution for seniors and their caregivers. The next-generation 4G device, however, is set to exponentially increase WHSI’s revenue base. The new device is telehealth ready, bluetooth capable and in high-demand from the company’s consumer base. However, supply chain issues set the release back and created a bit of an expectation gap for investors and consumers alike.
This is why WHSI leads our report as an oversold healthcare opportunity. The company has 8,000 end users plus an order book of about 2,000+ potential activations, which earned the company record revenues ($1.3 million) in 2021. Once its new device hits the market these numbers could explode.
WHSI has done its part to stoke interest with a marketing campaign on Kathy Ireland’s business show, and now the fruits of its labor are set to come to fruition, fortunately for investors the current market has created an opportunity to enter WHSI at a reasonable price prior to the catalytic events coming down the line.
Before you do anything, make sure to start your research on WHSI now:
On the subject of pipelines, Tonix Pharmaceuticals (NASDAQ: TNXP) CEO Seth Lederman, M.D. announced his company would be “Expanding the Pipeline of Vaccines”
Tonix Pharmaceuticals (NASDAQ: TNXP), a clinical-stage biopharmaceutical company, announced the United States Patent and Trademark Office Patent No. 11,345,896 to the Company on May 31, 2022 entitled “Synthetic Chimeric Poxviruses,” includes claims covering synthetic horsepox virus, the basis for the Company’s TNX-8011 vaccine in development to protect against monkeypox and smallpox and for the Company’s Recombinant Pox Virus (RPV) platform to protect against other pathogens, including SARS-CoV-2. This patent is expected to provide Tonix with U.S. market exclusivity until 2037, excluding any possible patent term extensions or patent term adjustments.
TNXP CEO Seth Lederman, M.D., commented: “This patent is an important milestone in protecting our expanding pipeline of vaccines that address known and potentially novel pathogens.TNX-801 is a horsepox-based live virus vaccine currently in development to protect against monkeypox and smallpox. TNX-18401 and TNX-18501 are designed to express the spike proteins from the SARS-CoV-2 omicron and BA.2 variants, respectively. Horsepox was one of the first few viruses ever generated by synthetic biology and remains among the largest.”
SIGA Technologies (NASDAQ: SIGA) was just awarded a contract from the US Department of Defense for the procurement of up to approximately $7.5 million of oral TPOXX, of which approximately $3.6 million of oral TPOXX is targeted for delivery in 2022 and the remainder is subject to an option at the sole discretion of the DoD. This is a hot topic because SIGA’s technology is meant to treat Monkeypox, which is at the top of the news cycle.
If you are in New York City next week, Chimerix (Nasdaq: CMRX) will be presenting at the Jefferies Healthcare Conference Wednesday June 8th. CMRX’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma. It is certainly another biotech worth investigating.
Finally, GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 3,030,304 shares of common stock at a purchase price of $1.65 per share. This capital raise will presumably help the company push its ongoing Phase 2 clinical trials of GEO-CM04S1 (formerly COH04S1) for COVID-19 as a universal booster vaccine to mRNA vaccines authorized by the U.S. Food and Drug Administration (FDA) and as a primary vaccine for use in immunocompromised patients.
Make sure to start your research today.
This article is part of a sponsored investor education program.